$IVST Innovest Global Inc $0.2750.01 +1.85% Innove
Post# of 42157
(Total Views: 100)
Posted On: 08/16/2018 11:09:19 AM
$
IVST
Innovest Global Inc $0.2750.01 +1.85% Innovest Global Provides August Shareholder Update with Milestones Including Patent Approval, Biotech Progress, Financial Achievements
CLEVELAND, Aug. 13, 2018 (GLOBE NEWSWIRE) -- Innovest Global Inc. (OTC Markets: IVST) (the “Company” or “Innovest”), a Conglomerate with operations in commercial and industrial products and services, and biotechnology, today announced notable financial progress, and having launched its Biotechnology & Health Services Division with significant achievements.
The Innovest Biotech Division launched with the acquisition of a twenty percent stake in StemVax Therapeutics, and with the news that the primary technology for the StemVax brain tumor vaccine had been granted patent approval after a nine year filing process. Immediately following this news, StemVax was granted exclusive worldwide rights from Cedars-Sinai Medical Center to this patent and three other technologies it will now use in its efforts to commercialize the vaccine.
Other notable July events include:
Winslow Asset Management, the first institutional investor in Innovest Global, filed showing that they remain long shareholder
First half 2018 revenue growth 55.8%
Current assets of $877,861
Cash balance of $561,062
Unchanged free-trading float of 11,796,710 common shares
No convertible debts, no warrants or options outstanding
Headcount is now 44 employees
Stock performance up 930% on the year (as of Friday August 10th, 2018 close).
Commercial & Industrial Division generated July monthly revenue of $351,763
The previously announced $650K+ Fortune 500 contract for providing call center services to Byram Healthcare Division was fully implemented, team trained and operational; “The Innovest team is highly professional, does an incredible job for us at the right price, and takes our business as seriously as we do,” said Perry Bernocchi, Chief Executive Officer of Byram Healthcare. “To our customers, they are part of the Byram team, and they’ve proven we can rely on them to be a proud part of our family.”
Advanced an acquisition initiative on a top priority target, kept others in discussion, and finalized our second half plan
About Innovest Global, Inc.
Innovest Global, Inc. (OTC Markets: IVST) is in the Conglomerates industry, a diversified holding company with operations in commercial and industrial products and services, energy, biotechnology, and health services. Innovest Global utilizes novel technology and marketing to efficiently acquire customers. Our primary growth strategy is to acquire existing companies in a select few industries, and attract new customers in cost effective ways. Currently, we have a Commercial & Industrial Division, and a Biotechnology & Health Services Division.
More about StemVax Therapeutics:
StemVax Therapeutics is a Translational Biotechnology Company that develops novel therapies for brain tumor patients. We focus our efforts on developing immunotherapeutic approaches to treating patients with Glioblastoma Multiforme (GBM), a devastating brain cancer. We also focus our research efforts on novel drug development to target Cancer Stem cells and other multi-resistant cancer cells. We seek to make a difference in patient’s lives. Bringing new beginnings to the market by developing novel therapeutics. Dr. Dwain Morris-Irvin, President of Innovest’s Biotech division is the StemVax founder and Chief Science Officer.
Cedars-Sinai Medical Center is a non-profit hospital and academic health science center located in Los Angeles, California. They employ over 2,000 physicians and are considered one of the top hospitals and research organizations in the world. Dr. Irvin previously was one of their key contributors in the areas of research that he founded StemVax to pursue.
For more information, please visit: http://www.innovestglobal.com, and follow us on Twitter @innovestglobal.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. All statements other than statements of historical facts included in this press release are forward-looking statements. These statements relate to future events or to the Company's future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Investors should not place any undue reliance on forward-looking statements since they involve known and unknown, uncertainties and other factors which are, in some cases, beyond the Company's control which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects the Company's current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to operations, results of operations, growth strategy and liquidity. Such risks, uncertainties and other factors, which could impact the Company and the forward-looking statements contained herein are included in the Company's filings with the OTC Markets. The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.
Contact Information
Corporate Office:
(216) 815-1122
info@innovestglobal.com
Twitter @innovestglobal
Investor Relations:
Hayden IR
(917) 658-7878
hart@haydenir.com
CLEVELAND, Aug. 13, 2018 (GLOBE NEWSWIRE) -- Innovest Global Inc. (OTC Markets: IVST) (the “Company” or “Innovest”), a Conglomerate with operations in commercial and industrial products and services, and biotechnology, today announced notable financial progress, and having launched its Biotechnology & Health Services Division with significant achievements.
The Innovest Biotech Division launched with the acquisition of a twenty percent stake in StemVax Therapeutics, and with the news that the primary technology for the StemVax brain tumor vaccine had been granted patent approval after a nine year filing process. Immediately following this news, StemVax was granted exclusive worldwide rights from Cedars-Sinai Medical Center to this patent and three other technologies it will now use in its efforts to commercialize the vaccine.
Other notable July events include:
Winslow Asset Management, the first institutional investor in Innovest Global, filed showing that they remain long shareholder
First half 2018 revenue growth 55.8%
Current assets of $877,861
Cash balance of $561,062
Unchanged free-trading float of 11,796,710 common shares
No convertible debts, no warrants or options outstanding
Headcount is now 44 employees
Stock performance up 930% on the year (as of Friday August 10th, 2018 close).
Commercial & Industrial Division generated July monthly revenue of $351,763
The previously announced $650K+ Fortune 500 contract for providing call center services to Byram Healthcare Division was fully implemented, team trained and operational; “The Innovest team is highly professional, does an incredible job for us at the right price, and takes our business as seriously as we do,” said Perry Bernocchi, Chief Executive Officer of Byram Healthcare. “To our customers, they are part of the Byram team, and they’ve proven we can rely on them to be a proud part of our family.”
Advanced an acquisition initiative on a top priority target, kept others in discussion, and finalized our second half plan
About Innovest Global, Inc.
Innovest Global, Inc. (OTC Markets: IVST) is in the Conglomerates industry, a diversified holding company with operations in commercial and industrial products and services, energy, biotechnology, and health services. Innovest Global utilizes novel technology and marketing to efficiently acquire customers. Our primary growth strategy is to acquire existing companies in a select few industries, and attract new customers in cost effective ways. Currently, we have a Commercial & Industrial Division, and a Biotechnology & Health Services Division.
More about StemVax Therapeutics:
StemVax Therapeutics is a Translational Biotechnology Company that develops novel therapies for brain tumor patients. We focus our efforts on developing immunotherapeutic approaches to treating patients with Glioblastoma Multiforme (GBM), a devastating brain cancer. We also focus our research efforts on novel drug development to target Cancer Stem cells and other multi-resistant cancer cells. We seek to make a difference in patient’s lives. Bringing new beginnings to the market by developing novel therapeutics. Dr. Dwain Morris-Irvin, President of Innovest’s Biotech division is the StemVax founder and Chief Science Officer.
Cedars-Sinai Medical Center is a non-profit hospital and academic health science center located in Los Angeles, California. They employ over 2,000 physicians and are considered one of the top hospitals and research organizations in the world. Dr. Irvin previously was one of their key contributors in the areas of research that he founded StemVax to pursue.
For more information, please visit: http://www.innovestglobal.com, and follow us on Twitter @innovestglobal.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. All statements other than statements of historical facts included in this press release are forward-looking statements. These statements relate to future events or to the Company's future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Investors should not place any undue reliance on forward-looking statements since they involve known and unknown, uncertainties and other factors which are, in some cases, beyond the Company's control which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects the Company's current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to operations, results of operations, growth strategy and liquidity. Such risks, uncertainties and other factors, which could impact the Company and the forward-looking statements contained herein are included in the Company's filings with the OTC Markets. The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.
Contact Information
Corporate Office:
(216) 815-1122
info@innovestglobal.com
Twitter @innovestglobal
Investor Relations:
Hayden IR
(917) 658-7878
hart@haydenir.com
(0)
(0)
What I post is my opinion. Do your own DD. Make your own investment decision. Links, images, & retweets are not endorsements.
1️⃣I do not provide personal investment advice and I am not a qualified licensed investment advisor. I am an amateur investor.
2️⃣All information found here, including any ideas, opinions, views, predictions, forecasts, commentaries, suggestions, or stock picks, expressed or implied herein, are for informational, entertainment or educational purposes only and should not be construed as personal investment advice. While the information provided is believed to be accurate, it may include errors or inaccuracies.
3️⃣I will not and cannot be held liable for any actions you take as a result of anything you read here.
4️⃣Conduct your own due diligence, or consult a licensed financial advisor or broker before making any and all investment decisions. Any investments, trades, speculations, or decisions made on the basis of any information found on this site, expressed or implied herein, are committed at your own risk, financial or otherwise.
1️⃣I do not provide personal investment advice and I am not a qualified licensed investment advisor. I am an amateur investor.
2️⃣All information found here, including any ideas, opinions, views, predictions, forecasts, commentaries, suggestions, or stock picks, expressed or implied herein, are for informational, entertainment or educational purposes only and should not be construed as personal investment advice. While the information provided is believed to be accurate, it may include errors or inaccuracies.
3️⃣I will not and cannot be held liable for any actions you take as a result of anything you read here.
4️⃣Conduct your own due diligence, or consult a licensed financial advisor or broker before making any and all investment decisions. Any investments, trades, speculations, or decisions made on the basis of any information found on this site, expressed or implied herein, are committed at your own risk, financial or otherwise.
Scroll down for more posts ▼